Login to Your Account

FDA Briefing Docs: Preclinical Cancer a Worry for Isis Drug

By Randy Osborne
Staff Writer

Tuesday, October 16, 2012
Unexpected news for investors cropped up in briefing documents posted online by the FDA about Isis Pharmaceuticals Inc.'s lead cholesterol-lowering, antisense candidate Kynamro (mipomersen), and shares of the company took a daylong dive Tuesday as hopes for a positive vote weakened.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription